Trinity Biotech buys Xtrana's Biopool unit:
This article was originally published in Clinica
Dublin, Ireland-based Trinity Biotech is to buy the assets and goodwill of Xtrana's Biopool haemostasis division for $6.25 million, with an initial $3.6 million paid immediately and the remainder over a 36-month period. Biopool has operations in Ventura, California, and in Umea, Sweden. The acquisition will take Trinity into a segment of the clinical laboratory market where it was not previously present, as well as strengthening its portfolio with over 50 additional products, Trinity says. It will also boost US distribution.